Please login to the form below

Not currently logged in

Takeda expands into Brazil

Takeda, Japan's largest drug company, has announced it is to establish a commercial subsidiary in Brazil

Takeda, Japan's largest drug company, has announced it is to establish a commercial subsidiary in Brazil.

The new operation, which will be based in Sao Paulo, will import and commercialise Takeda products for the Brazilian market.

This latest expansion by the Japanese company is the twelfth in as many months following the establishment of subsidiaries in Belgium, Canada, Denmark, Ireland, Luxembourg, Mexico, Norway, Portugal, Spain, Sweden and Turkey.

"Combined with Takeda's additional recent expansions, this opportunity will drive Takeda's ability to maximise the potential of our pipeline in Brazil," said Alan MacKenzie, executive vice president international operations, Takeda Pharmaceuticals International.

"Brazil is an important country in the Latin American region for Takeda to ensure we are providing our products where patients need them."

With a population of around 196 million people, Brazil is the largest country in Latin America and accounts for more than 40 per cent of pharmaceutical sales in the region. Pharmaceutical sales in the country are forecast to grow by 8.5 per cent each year until 2013.

2nd December 2009


Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...